https://africanjournalofbiomedicalresearch.com/index.php/AJBR
Afr. J. Biomed. Res. Vol. 27(4s) (November 2024); 2581-2596
Research Article

A study on investigating operational management tools and methodologies to improve the efficiency in patient-centric clinical trials in bio-pharmaceuticals.

Prasanna Kumar C S[1*], Saisree Mangu[2]

[1*]Research Scholar, GITAM School of Business , GITAM University, Bengaluru, ORCID ID : 0009-0009-2986-6098
[2] Faculty Member GITAM School of Business, GITAM University, Bengaluru, ORCID ID : 0000-0003-1276-2021

Abstract
This approach, in modern healthcare research, is known to emphasize placing the patients at the center of the trial process. Operational management tools and strategies would thus be necessary in this process together for sustainable development of patient centric otherwise create inefficiency in the trial process and noncompliance. Against this backdrop, this study would assist in exploring the possibility of integrating operational management models within the patient-centric clinical trial, that is how strategies associated with enhancing data collection and management, informed consent, and lifestyle of patients may be embraced. It explores the need for adopting customized management of operations to optimize trial procedures, yet with awareness about patient's needs and rights. Topics include advanced technologies used in data collection and management, proper and informed consent procedure, and overcoming legal barriers.For the most part, this paper entails a comprehensive review of factors that are widely relevant in determining better efficiency and effectiveness of patient-centric clinical trials. Ultimately, these insights lead to sustainable practices in healthcare research, and in influencing sustainable societies for patient outcomes while providing practical implications for practitioners on how best to implement these methodologies in their patient centric trial processes.

Keywords: Patient-centric clinical trial, Operational management models, sustainability development, health promotion in sustainable societies

Author for Correspondence: email: psuryapr@gitam.in

Received 14/11/2024, Acceptance 21/11/2024

DOI: https://doi.org/10.53555/AJBR.v27i4S.4072

1 Introduction

Clinical studies are crucial for testing new medications and therapies to ensure they are safe and effective before being made available to patients. However, traditional clinical trial processes often encounter issues related to operational inefficiencies and legal obstacles, delaying the delivery of innovative treatments to patients,(Bonham, 2011). In recent times, there has been elevating attention on adopting patient-centered approaches in clinical trials to enhance participant involvement, enhance data accuracy, and expedite the drug development process,(Cham, 2019).This study points to investigating operational administration devices and techniques that can increment the effectiveness of patient-centric clinical trials whereas tending to lawful boundaries. By leveraging inventive procedures and advances, clinical trial supports, analysts, and administrative specialists can streamline

trial operations, upgrade understanding encounters, and explore complex legitimate systems more viably (DiMasi, 2003).

Overall, this examination points to supply experiences into optimizing the conduct of patient-centric clinical trials through viable operational administration procedures while guaranteeing adherence to legitimate and administrative systems. By improving the effectiveness and straightforwardness of clinical trial forms, partners can eventually progress restorative research and provide inventive medications to patients more quickly and responsibly(Getz, 2006). Data security controls, such as the General Data Protection Regulation (GDPR) in Europe and the Health Insurance Portability and Accountability Act (HIPAA) within the United States, necessitates the collection, capacity, and utilization of data related to individual well-being in clinical inquiry. Analysts must actualize strong information administration frameworks and security measures to defend persistent secrecy, avoid unauthorized revelation, and comply with jurisdiction-specific security laws (Reis, 2018).

Mental property rights administer the possession, authorizing, and commercialization of inquiry about discoveries, counting licenses, copyrights, and trademarks. Collaborative inquiry about ascension and mental property arrangements ought to clarify possession rights, distribution rights, and revenue-sharing courses of action to incentivize development, while securing the interface of all parties included (Brooks, 2012).

In conclusion, patient-centric clinical trials speak to a promising approach to progressing therapeutic inquiry and making strides with persistent results (English, 2010). By prioritizing quiet needs and points of view, these trials can upgrade member engagement, enrollment, maintenance, and information quality, ultimately accelerating the advancement and conveyance of inventive medications (Huang, 2020). In any case, operationalizing patient-centricity requires cautious arranging, coordination, and usage, as well as adherence to lawful and administrative systems administering clinical inquiry. By tending to these challenges and contemplations, partners can maximize the benefits of patient-centric trials while guaranteeing moral conduct, compliance, and understanding security (Reddy, 2016).

1.1 Aim and Objectives of the Study

The aim of the study is to research different operational management tools and methodologies to develop unique strategies in order to increase the efficiency of patient-centric clinical trials and address legal barriers. In accordance with the aim, the following objectives will be covered here:

- To investigate the different operational management tools and research methods adopted in clinical trial
- To research the sustainable development challenges & legal barriers in patient-centric research and the need for such research
- To explore the applicability of operation management tools and adoption of sustainable lifestyles of participants in patient-centric trials
- To analyze doctors and bio-pharmaceutical company manager's perceptions regarding the adoption of different operation management tools to promote sustainable societies.

2.0 Literature Review

2.1 Operational Management Models

Operational management models are basic components in guaranteeing the effectiveness and adequacy of clinical trials, which are fundamental for the advancement of modern medical medications and interventions (Ozdemir, 2011). One such demonstration that has picked up critical consideration is the Six Sigma approach. Initially developed within the manufacturing industry, Six Sigma points to minimize variability and defects in forms, eventually driving to improved quality and results (Califf, 2003). When connected to clinical trials, Six Sigma standards can be utilized over different viewpoints of trial administration, counting convention advancement, persistent enrollment, information collection, and investigation.

The applicability of the Six Sigma approach in clinical trials lies in its capacity to distinguish and address root causes of inefficiencies and errors (Eisenstein, 2004). Through the utilization of strategies such as define, degree, analyze, improve, and control (DMAIC), clinical trial groups can methodically evaluate forms, recognize zones for advancement, and actualize data-driven arrangements. For instance, Six Sigma can offer assistance in streamlining persistent enrollment forms by recognizing bottlenecks and actualizing techniques to upgrade quiet engagement and retention (Mazor, 2016).

Besides, Six Sigma standards can be connected to information administration and investigation, guaranteeing the exactness and unwavering quality of trial information. By setting up vigorous information collection conventions and executing quality control measures, clinical trial groups can minimize mistakes and guarantee the keenness to consider results (Califf, 2011). Also, Six Sigma strategies can be utilized to optimize asset assignment and budget administration, maximizing the proficiency of trial operations whereas minimizing costs.

Within the setting of convention advancement, Six Sigma can assist in making streamlined and standardized conventions that diminish inconstancy and enhance study reproducibility, (Eisenberg, 2011). This could lead to more effective trial execution and improved information quality, eventually quickening the medicate advancement handle (Leonard, 2004). Besides, Six Sigma can encourage persistent advancement endeavors all through the trial lifecycle, permitting groups to recognize and address issues as they emerge, subsequently upgrading generally trial performance (Parviainen, 2017).

One of the key benefits of adopting Six Sigma in clinical trials is its focus on evidence-based decision-making (Getz, 2008). By using data-driven approaches

to identify and prioritize areas for improvement, clinical trial teams can ensure that resources are allocated effectively and interventions are implemented efficiently. This can result in faster study completion and improved patient outcomes. Additionally, Six Sigma fosters a culture of continuous improvement within clinical trial organizations, encouraging collaboration and innovation among team members (Nudurupati, 2015). By promoting a systematic approach to problem-solving and process optimization, Six Sigma enables trial teams to work together towards common goals and objectives.

In summary, the Six Sigma approach offers an efficient and data-driven framework for optimizing operational management in clinical trials. By leveraging Six Sigma principles and tools, trial teams can enhance efficiency, improve quality, and ultimately contribute to the successful conduct of clinical research (Eisenstein, 2008). As the bio-pharmaceutical industry continues to evolve, the adoption of Six Sigma methodologies is likely to become increasingly important in driving innovation and improving patient outcomes.

2.2 Clinical Trials Research Methodologies

The research techniques for clinical trials , especially randomized controlled trials (RCTs), are essential within the time of evidence-based medication for assessing the security and adequacy of restorative mediations. RCTs are broadly respected as the gold standard for evaluating treatment adequacy, as they offer assistance to minimize bias and confounding factors by randomly assigning members to treatment and control groups (Mas-Tur, 2020). This randomization preparation guarantees that the groups are comparable, permitting analysts to point out contrasts in results to the intercession being considered. However, despite their qualities, RCTs also have limitations that have to be recognized and tended to (Imison, 2016). One such restriction is the potential for choice predisposition, especially in case members are not randomly chosen or in case there are contrasts between treatment groups at baseline (Springer, 2020). This could undermine the inner legitimacy of the study results and compromise the capacity to draw precise conclusions approximately the intervention's viability. Furthermore, RCTs may not continuously be attainable or moral, particularly in cases where withholding treatment from a control group pose posture dangers to members (Clinical Trials Help Groups, 2010).

To supplement RCTs and mitigate some of their challenges, alternative clinical trial research methods, such as observational studies, offer alternative approaches to generate real-world evidence on treatment effects (Getz, 2007). Observational studies, including cohort studies and case-control studies, allow researchers to observe outcomes in natural settings without intervention (Eisenstein, 2008). While observational studies provide valuable insights into treatment effects in diverse patient populations, they are susceptible to biases such as confounding and selection bias. Researchers must carefully acknowledge these limitations when interpreting the findings of observational studies and ensure appropriate statistical methods are used to mitigate bias. Additionally, innovative clinical trial designs, such as adaptive trial designs, have emerged to address some of the challenges associated with traditional RCTs.

Adaptive trial designs allow for adjustments to the trial protocol based on interim analyses of accumulating data, enabling researchers to make real-time adjustments to optimize trial efficiency and resource allocation (Getz, 2008). These novel approaches offer flexibility and efficiency in trial conduct, potentially reducing costs and expediting the drug development process. In addition to considering the strengths and limitations of different research methods, researchers must also adhere to ethical principles and regulatory requirements when designing and conducting clinical trials. Ethical considerations, such as obtaining informed consent from participants and ensuring patient safety, are paramount in clinical research (Dilts, 2006). Regulatory compliance with guidelines set forth by regulatory agencies, such as the Food and Drug Administration (FDA) in the United States, is essential to ensure the integrity and validity of clinical trial data. Overall, clinical trial research methods play a crucial role in advancing medical knowledge and informing clinical practices. By carefully evaluating the strengths and limitations of various methods, researchers can design studies that provide reliable and meaningful evidence to guide healthcare decision-making (Manogaran, 2017). As the field of clinical research continues to evolve, ongoing innovation and collaboration among researchers will be essential to address emerging challenges and enhance the quality and efficiency of clinical trials (Cutting Edge Information, 2011).

2.3 Patient-Centric Trial and Legal Challenges

Patient-centric trials represent a significant advancement in clinical research methodology, prioritizing the dynamic association and strengthening of patients all through the trial preparation. Unlike conventional trials where patients are detached members, patient-centric trials see patients as accomplices for enquiry. Such trials put emphasis on their input, points of view, and encounters. The center rule of patient-centricity spins around planning trials that adjust with persistent needs, preferences, and needs, eventually pointing to improving the pertinence and effect of investigating outcomes (Getz, 2008). By incorporating patient voices from the start, these trials cultivate a more collaborative and comprehensive approach to clinical investigation (Klewes, 2017).

One of the key traits of patient-centric trials is the accentuation of persistent patient association in all stages of inquiry. From the initial planning stage, patients play a dynamic part in forming the direction of the trial. Their input illuminates choices with respect to thinking about destinations, intercessions, result measures, and enrollment procedures, guaranteeing that trials are custom-made to address patient-centered concerns and targets. By including patients as co-creators of research, patient-centric trials improve the

significance, worthiness, and appropriateness of ponder discoveries to real-world clinical practices (Damodaran, 2007).

Patient education and strengthening are crucial columns of patient-centric trials, pointing to guarantee that patients are well-informed and effectively locked in in their healthcare choices (DiMasi, 2004). Comprehensive and straightforward communication is fundamental to supply patients with a clear understanding of the trial reason, strategies, potential risks, and benefits (Kohl, 2019). Patients are engaged to form educated choices through their cooperation, guided by their preferences, values, and objectives. Moreover, patient-centric trials offer back administrations and assets to address down-to-earth obstructions of interest such as transportation, childcare, and dialect obstructions. In this manner patient inclusivity and availability is enhanced (Clinical Trials Transformation Initiative, 2011).

Adaptability and versatility are necessarily highlights of patient-centric trials, permitting for personalized approaches to meet personal needs and inclinations (Laurenza, 2018). Versatile trial plans, for instance, empower real-time alterations to conventions based on developing information or quiet criticism, optimizing trial effectiveness and significance,(Kostkova2015). By grasping adaptability, patient-centric trials can suit different populations, counting those with unique medical conditions, social foundations, or treatment inclinations. In this manner, the generalizability and pertinence of ponder discovery is upgraded (Clinical Trials Transformation Initiative, 2011).

In spite of the transformative potential of patient-centric trials, they moreover display special legitimate challenges that must be tended to guarantee ethical conduct, regulatory compliance, and quiet security. Informed consent may be a foundation of moral research practice, requiring analysts to get deliberate, educated assent from members (Eisenberg, 2011). In patient-centric trials, where patients are more effectively locked in decision-making, analysts must maintain thorough benchmarks for educated assent to secure quiet autonomy and rights.

Data privacy and confidentiality are vital contemplations in patient-centric trials, given the delicate nature of patient information collected amid the investigation. Analysts must execute vigorous information assurance measures to defend quiet information and comply with pertinent security directions such as the Health Insurance Portability and Accountability Act (HIPAA) within the United States (Monti, 2016). Also, analysts must follow administrative necessities forced by administering bodies such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA) to guarantee the legitimacy, keenness, and adequacy of trials. Compliance with directions overseeing trial conduct, information collection, and announcing is fundamental to maintain moral benchmarks and the belief in clinical inquiry (Downing, 2012).

Identifying research gaps is pivotal in any consideration to highlight zones where advance examination or exploration is justified. Through the audit of existing writing, certain gaps in information were cleared, making way for future investigation endeavors. Within the setting of this study on patient-centric trials and operational administration in clinical research, a few research gaps have risen that justify consideration and investigation. One eminent research gap relates to the shortage of comprehensive rules or systems for executing patient-centric trials in diverse clinical settings. While there is developing acknowledgment of the significance of persistent engagement in research, there remains a need for standardized approaches or best practices for operationalizing patient-centricity over distinctive helpful regions, study plans, and healthcare settings. Addressing this gap requires the advancement of practical rules or toolkits that give analysts, clinicians, and partners with actionable techniques and assets for consolidating viewpoints and needs into trial plan, conduct, and evaluation.

Another research gap lies within the restricted understanding of the effect of patient-centric trials on clinical results, healthcare conveyance, and quiet encounters. While there is anecdotal evidence proposing that persistent engagement can improve pertinence, enrollment, and maintenance, experimental research is required to measure the benefits and challenges related with patient-centric approaches (DiMasi, 2005). Thorough assessment ponders comparing patient-centric trials to conventional trial models are required to survey the adequacy, productivity, and maintainability of persistent engagement procedures in accomplishing research targets and improving patient-centered results. Furthermore, there is a lack of inquiry about analyzing the part of operational administration instruments and strategies in optimizing the conduct and productivity of patient-centric trials (Deloitte, 2009). While there is anecdotal evidence recommending that apparatuses like Six Sigma or incline administration can progress trial processes and results, experimentalists are required to methodically assess their effect on key execution markers such as trial term, quality, and member fulfillment (Patrício, 2019). Understanding how operational administration standards can be custom-made to the one-of-a-kind needs and challenges of patient-centric trials is the basis for improving trial efficiency and viability (Kivimaa, 2019).

Additionally, there are constrained inquiries about investigating the legal and administrative suggestions of patient-centric trial models, especially within the setting of information protection, educated assent, and administrative compliance. As quiet engagement increases in clinical research, it is essential to guarantee that trial conventions follow moral and administrative benchmarks while defending quiet rights and confidentiality (Kraus, 2020). Research exploring the

legal and moral considerations encompassing patient-centric trials can illuminate the improvement of rules, arrangements, and preparing programs to support analysts and supports in exploring complex legal landscapes while advancing patient-centered research practices (Embi, 2005).

In rundown, tending to these research holes requires intriguing collaboration, methodological development, and partner engagement to progress knowledge and practice in patient-centric trials and operational administration in clinical research (Nuffield Trust, 2019) By prioritizing these ranges for future examination, analysts can contribute to the continuous advancement and improvement of patient-centered approaches to clinical research (Melchiorre, 2018).

3.0 Methods and Materials

Research Design

The research methodology employed in this study is designed to gather quantitative data through a survey-based questionnaire instrument. This approach was chosen for its ability to systematically collect standardized data from a large and diverse sample population. By utilizing a quantitative questionnaire, the study aims to obtain numerical data that can be analyzed statistically to draw meaningful conclusions and insights regarding patient-centric trials and operational management in clinical research (Davis, 1999).

Data collection

The instrument used for data collection is a Likert 5 point scale-based quantitative questionnaire specifically tailored to assess the perspectives, practices, and experiences of doctors and managers in bio-pharmaceutical companies regarding patient-centric trials. The questionnaire comprises structured items with predefined response options, allowing respondents to provide quantitative ratings or responses to various aspects of patient engagement, operational management strategies, and perceived barriers and facilitators to conducting patient-centric trials.

Target population

The target population for this study consists of doctors and managers working in bio-pharmaceutical companies involved in clinical research activities. This population was selected based on their direct involvement in designing, implementing, or overseeing patient-centric trials and their expertise in operational management within the bio-pharmaceutical industry. By focusing on this specific population, the study aims to capture insights and perspectives from key stakeholders with firsthand experience and knowledge of patient-centric trial practices and challenges.

Sample size

In the study, a combination of stratified sampling and convenience sampling was employed to ensure the representativeness and diversity of the sample. Stratified sampling involved dividing the target population into homogeneous subgroups based on factors such as job role, therapeutic area, and company size, with random selection of samples from each subgroup. This approach facilitated inclusion of participants from various demographic and organizational backgrounds, thereby enhancing the generalizability of the findings. Additionally, convenience sampling was utilized to recruit participants from accessible sources such as professional networks, industry conferences, and online forums, despite the potential for sampling bias. While convenience sampling may introduce some degree of bias, its practical advantages in terms of cost-effectiveness, time efficiency, and accessibility were considered beneficial, especially when targeting specific professional populations such as doctors and managers in bio-pharmaceutical companies. The anticipated sample size of 385 members was determined based on considerations of statistical power, precision, and feasibility, aiming to ensure adequate representation of the target population and enhance the reliability and validity of the study findings. By recruiting a diverse and representative sample, the study aimed to capture a comprehensive range of perspectives and experiences related to patient-centric trials and operational management in clinical research among doctors and managers in bio-pharmaceutical companies.

3.1 Data Analysis Tools

To analyze the quantitative data collected, the study will employ statistical package for the Social sciences (SPSS) software. Demographic analysis was done to summarize the major aspects associated with common aspects associated with participants. Descriptive statistics was employed on the data collected using a questionnaire to summarize and describe the main characteristics of the dataset including measures of central tendency (e.g., mean and median) and variability (e.g., standard deviation and range). Inferential statistical techniques such as reliability, validity, and confirmatory analysis were performed on the data obtained. Preliminary model was generated using the main variables of the study and AMOS was performed for determining the good fit of the model and the covariance across the major variables identified in the study.

4.0 Results

4.1 Demographic analysis

A total of 385 respondents were considered for the study. Of the 385 respondents, males and females were in equal proportions (1A). Exactly 43% of the total respondents were above 51 years (1B). Exactly 38% of respondents had the experience of more than 11-15 years (1C). Exactly 40% of the respondents had the experience of 7-9 clinical trials (1D). A total of 72% of respondents had an idea regarding operational tools and patient centric tools (1E).



Fig 1: Demographic analysis of the respondents

Observation 1

The descriptive statistics provided offer valuable insights into the distribution and variability of responses for different statements related to operational management (OM) in the context of clinical trials. By examining the mean, standard deviation, minimum, and maximum values, researchers can gain a deeper understanding of the data and identify trends or patterns that may inform decision-making processes.

One notable observation from the table is the variability in mean values across different statements. For instance, the statement "OM6" has the highest mean value of 3.97, indicating that respondents, on average, rated this statement relatively high in terms of agreement or importance. On the other hand, the statement "OM1" has a lower mean value of 3.87, suggesting that respondents tended to rate this statement slightly lower compared to others. This discrepancy in mean values may reflect variations in perceptions or attitudes toward different aspects of operational management in clinical trials.

The standard deviation values provide insights into the dispersion or variability of responses around the mean. A smaller standard deviation indicates that responses are closely clustered around the mean, suggesting greater agreement or consensus among respondents. Conversely, a larger standard deviation suggests greater variability in responses, indicating a wider range of opinions or perspectives among participants.

In this case, the standard deviations for all statements range from 0.455 to 0.601, indicating relatively low to moderate levels of variability in responses across different statements. This suggests that while there may be some differences in opinions or perceptions among respondents, there is generally a degree of agreement or consistency in how these statements are perceived.

It is also important to consider the minimum and maximum values, as they provide additional context regarding the range of responses observed for each statement. The minimum value represents the lowest rating assigned to a statement, while the maximum value represents the highest rating. By examining these values, researchers can identify the full spectrum of responses and assess the overall distribution of opinions or attitudes.

Overall, the descriptive statistics offer a comprehensive overview of respondents' perceptions of operational management in clinical trials. By analyzing these statistics, researchers can identify key areas of strength or concern and tailor interventions or strategies accordingly. Additionally, researchers can use this information to compare responses across different demographic or organizational groups, allowing for a more nuanced understanding of the factors influencing perceptions of operational management in clinical trials. Moving forward, researchers may consider conducting further analyses, such as inferential statistics or qualitative interviews, to explore the underlying reasons behind respondents' perceptions and attitudes,(DiMasi,2010). Additionally, longitudinal studies could be conducted to assess changes in perceptions over time and evaluate the effectiveness of interventions aimed at improving operational management practices in clinical trials. By employing a multi-faceted approach, researchers can gain deeper insights into the complex dynamics of operational management in clinical trials and identify opportunities for improvement.

Observation 2

The provided descriptive statistics offer insights into the distribution and variation of responses for different statements within four distinct categories: Organizational Management (OM), Customer Relationship Management (CTRM), Product Customization (PCT), and Logistics Coordination (LC). By analyzing the mean values and standard deviations, we can discern patterns and assess the relative agreement or dispersion of responses.

In the domain of Organizational Management (OM), Statement OM6 stands out with a high mean value of 3.97 and a relatively low standard deviation of 0.481, indicating a strong consensus among respondents regarding this statement. Conversely, Statement OM1 exhibits a lower mean value of 3.87 and a slightly higher standard deviation of 0.597, suggesting more variability in respondents' perceptions. These findings imply that while OM6 reflects a widely agreed-upon sentiment within the sample, opinions on OM1 are more diverse.

Moving to Customer Relationship Management (CTRM), the data show that Statement CTRM2 has the highest mean value of 3.95, coupled with a low standard deviation of 0.435, indicating a high level of agreement among respondents. Conversely, Statement CTRM1 has a slightly lower mean value of 3.93 and a similar standard deviation of 0.455, suggesting a comparable level of consensus but with a marginally lower average rating. This implies that while both statements are generally agreed upon, CTRM2 might be perceived slightly more positively than CTRM1.

In the realm of Product Customization (PCT), Statement PCT2 emerges with the highest mean value of 3.91 and a standard deviation of 0.514, indicating a relatively high level of agreement but with slightly more variability compared to other statements. Conversely, Statement PCT1 has a lower mean value of 3.88 and a higher standard deviation of 0.591, suggesting a less consistent consensus among respondents. These findings suggest that while there is general agreement on both statements, PCT2 might be perceived more positively and with slightly less variability.

Lastly, in Logistics Coordination (LC), Statement LC3 stands out with the highest mean value of 3.94 and the lowest standard deviation of 0.422, indicating a strong consensus and minimal variability among respondents. Conversely, Statement LC1 has a lower mean value of 3.88 and a relatively high standard deviation of 0.591, suggesting a less consistent agreement among respondents. This suggests that while respondents generally agree on the positive sentiment expressed in LC3, opinions on LC1 vary more widely.

In summary, the provided descriptive statistics offer valuable insights into the perceived effectiveness or importance of various statements within each domain. While some statements enjoy strong consensus and minimal variability (e.g., OM6 and LC3), others exhibit lower mean values and higher variability (e.g., OM1 and PCT1), indicating a more diverse range of opinions. Understanding these patterns can inform decision-making processes, highlighting areas of strength and areas for potential improvement within each domain.

4.2. Reliability Statistics

The reliability analysis conducted using SPSS revealed high internal consistency across all scales, with Cronbach's alpha values ranging from 0.819 to 0.894. Specifically, the operational management model exhibited a Cronbach's alpha of 0.847, clinical trial research methodologies scale 0.894, patient-centric trials scale 0.819, and legal challenges associated with clinical trials scale 0.814. A summary of the reliability testing is presented in Table 1.

Overall, these reliability statistics provide assurance regarding the quality and consistency of the data collected for the study, lending credibility to the findings and conclusions drawn from the analysis. It is essential to consider these reliability measures while interpreting the results and drawing implications for practice and future research in the field of clinical trial management and research methodologies. This suggests that the data collected across multiple dimensions related to organizational management, clinical trial research methodologies, patient-centric trials, and legal challenges exhibit high internal consistency and reliability (Collier, 2009).

Table 1: Reliability testing of various parameters

Parameters	**Crohnbach's alpha (α)**
Operational Management Models	0.847
Clinical Trial Research Methodologies	0.894
Patient Centric Trial	0.819

4.3. Confirmatory Factor Analysis

The principal component analysis was carried out to reduce a large set of data to obtain a meaningful smaller set of constructs. Each variable used in the analysis was measured by multi- item constructs by factor analysis with varimax rotation to check the unidimensionality among the items. All the items included in the analysis had factor loadings of 0.4. When all the items were forced to form a single factor, the factor analysis was able to extract 4 components with a variance of 62.049%. A summary of PCA analysis is presented in Table 2.

Table 2: PCA for factor analysis

	Component			
	1	2	3	4
OM1	.409	.416		.635
OM2	.484			.754

OM3	.692			
OM4	.401	.473	.473	
OM5		.572	.401	
OM6			.747	
OM7	.608	.472		
OM8		.461	.530	
OM9	.625			
CTRM1	.692			
CTRM2	.581		.428	
CTRM3	.581		.428	
CTRM4	.692			
CTRM5	.692			
CTRM6	.692			
CTRM7	.692			
CTRM8	.692			
CTRM9	.692			
PCT1		.775		
PCT2	.424	.620		
PCT3			.619	
PCT4		.466	.616	
PCT5		.789		
LC1		.775		
LC2		.686		
LC3			.607	
LC4		.439	.643	
LC5		.695		

A preliminary model was constructed and tested for confirmatory factor analysis.



Fig 2: Path diagram for CFA showing model fit indices

The different values obtained for model fit indices are presented in Table 3.

Table 3: The values for model fit indices based on path diagram

	Model fit	**Desired score**
Chi – Square	466.666	NA
Degrees of Freedom	347	NA
CMIN/DF	1.345	</=2.00 for good fit and 2.00 – 5.00 for moderate fit.
CFI	0.901	Close to or more than 0.90 for good fit
RMSEA	0.059	</=0.10 reflects good fit
NFI	0.706	Value close to 0.90 reflects a good fit

The chi square value was 466.666, DF was 347, and the CMIN/DF was 1.345, indicating a good fit model. The CFI was 0.901, which is close to 0.9. RMSEA was 0.059 indicating a good fit. However, the value of NFI was close to 0.9 indicating a good fit. Thus, preliminary model analysis shows a good fit for the model.

Validity

This indicated the assessment and validation by using the discriminant and convergent validity. The convergent validity was also assessed by using the factor loadings of latent constructs, which had a significant p value less than 0.001. This test supported that the constructs had convergent validity. The discriminant validity indicated by correlation matrix where majority of the constructs had a correlation coefficient of less than 0.85 and also by using the path analysis where the correlations among the latent constructs were less than 1.

A preliminary model was set for the confirmatory factor analysis by using AMOS. The preliminary model allowed the researcher for its best fit as per parsimony and substantive meaningfulness. The model fit indices indicated how the underlying structure fits the data. The model was evaluated by using the model fit indices including Chi Square statistic, degrees of freedom (DF), CMIN/DF, CFI, and RMSEA. The model is presented in Fig 3.



Fig 3: Model for CFA

The overall model fit indices are presented in Table 4.

Table 4: Model fit indices

	Model fit	**Desired score**
Chi – Square	260.623	NA
Degrees of Freedom	344	NA
CMIN/DF	0.758	</=2.00 for good fit and 2.00 – 5.00 for moderate fit.
CFI	1.0	Close to or more than 0.90 for good fit
RMSEA	0.000	</=0.10 reflects good fit
NFI	0.836	Value close to 0.90 reflects a good fit

The chi square value was 260.623 DF was 344 and the CMIN/DF was 0.758, indicating a good fit model. The CFI was 1.0, which is close to 0.9. RMSEA was 0.000 indicating a good fit. However, the values of NFI were close to 0.9 indicating a good fit.
Association between variables is summarized in the covariance table presented (Table No.5).

Table 5: Covariance Table

			Estimate	S.E.	C.R.	P	Label
OM	<-->	LC	.155	.033	4.686	***	
CTRM	<-->	LC	.094	.022	4.227	***	
PCT	<-->	LC	.189	.037	5.094	***	
CTRM	<-->	PCT	.092	.022	4.162	***	
OM	<-->	PCT	.154	.033	4.671	***	
OM	<-->	CTRM	.120	.026	4.675	***	

There is statistically significant association seen between the variables as per the models presented, thus giving high reliability and validity to the data.

Descriptive statistics
The Likert scale questionnaire was developed and its evaluation was done statistically. The descriptive statistics provided offer valuable insights into the distribution and variability of responses for different statements related to operational management (OM) in the context of clinical trials. By examining the mean, standard deviation, minimum value, and maximum value, researchers can gain a deeper understanding of the data and identify trends or patterns that may inform decision-making processes.
The provided descriptive statistics offer insights into the distribution and variation of responses for different statements within four distinct categories: organizational management (OM), customer relationship management (CTRM), product customization (PCT), and logistics coordination (LC). By analyzing the mean values and standard deviations, we can discern patterns and assess the relative agreement or dispersion of responses.

Organizational Management
In the domain of organizational management (OM), Statement OM6 " **I believe that adaptive trial designs can contribute to more successful and patient-centric clinical trials benefitting both doctors and patients"** stands out with a high mean value of 3.97 and a relatively low standard deviation of 0.481, indicating a strong consensus among respondents regarding this statement. Conversely, Statement OM1 "**I believe that the strategy to monitor high-risk areas in patients and drug applications is an effective strategy for enhancing patient safety in clinical trials "** exhibits a lower mean value of 3.87 and a slightly higher standard deviation of 0.597, suggesting more variability in respondents' perceptions. These findings imply that while OM6 reflects a widely agreed-upon sentiment within the sample, opinions on OM1 are more diverse.

Table 6: Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
OM1	100	1	5	3.87	.597
OM2	100	1	5	3.89	.601
OM3	100	1	5	3.93	.455
OM4	100	1	5	3.93	.498
OM5	100	1	5	3.89	.549
OM6	100	1	5	3.97	.481
OM7	100	1	5	3.90	.522
OM8	100	1	5	3.94	.509
OM9	100	1	5	3.95	.458
Valid N (listwise)	100				

Customer relationship management
Moving to customer relationship management (CTRM), the data show that Statement CTRM2 " **I believe that randomized controlled trials can aid in assessing the efficacy of treatments or interventions in a more efficient and patient-centric approach"** has the

highest mean value of 3.95, coupled with a low standard deviation of 0.435, indicating a high level of agreement among respondents. Conversely, Statement CTRM1 "**Random assignment of participants to different treatment groups is crucial for minimizing bias and ensuring fair comparison of different groups in clinical trials'' has** a slightly lower mean value of 3.93 and a similar standard deviation of 0.455, suggesting a comparable level of consensus but with a marginally lower average rating. This implies that while both statements are generally agreed upon, CTRM2 might be perceived slightly more positively than CTRM1.

Descriptive Statistics

Table 7: Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
CTRM1	100	1	5	3.93	.455
CTRM2	100	1	5	3.95	.435
CTRM3	100	1	5	3.95	.435
CTRM4	100	1	5	3.93	.455
CTRM5	100	1	5	3.93	.455
CTRM6	100	1	5	3.93	.455
CTRM7	100	1	5	3.93	.455
CTRM8	100	1	5	3.93	.455
CTRM9	100	1	5	3.93	.455
Valid N (listwise)	100				

Product Customization

In the realm of product customization (PCT), Statement PCT2 " **According to me, patient-centred trial designs can improve participant satisfaction and willingness to participate in future studies"** emerges with the highest mean value of 3.91 and a standard deviation of 0.514, indicating a relatively high level of agreement but with slightly more variability compared to other statements. Conversely, Statement PCT1 " **I think that engaging patients throughout the trial process can enhance the overall quality of clinical trial data"** has a lower mean value of 3.88 and a higher standard deviation of 0.591, suggesting a less consistent consensus among respondents. These findings suggest that while there is general agreement on both statements, PCT2 might be perceived more positively and with slightly less variability.

Descriptive Statistics

Table 8: Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
PCT1	100	1	5	3.88	.591
PCT2	100	1	5	3.91	.514
PCT3	100	1	5	3.93	.477
PCT4	100	1	5	3.93	.477
PCT5	100	1	5	3.92	.486
Valid N (listwise)	100				

Logistic coordination

Lastly, in logistics coordination (LC), Statement LC3 "**Balancing the need for scientific advancement with ethical principles can be challenging in the evolving landscape of clinical research which can lead to a reduction in the efficiency of clinical trials"** stands out with the highest mean value of 3.94 and the lowest standard deviation of 0.422, indicating a strong consensus and minimal variability among respondents. Conversely, Statement LC1 "**I believe that navigating regulatory requirements is a significant challenge in the planning and execution of clinical trials"** has a lower mean value of 3.88 and a relatively high standard deviation of 0.591, suggesting a less consistent

agreement among respondents. This suggests that while respondents generally agree on the positive sentiment expressed in LC3, opinions on LC1 vary more widely.

Descriptive Statistics

Table 9: Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
LC1	100	1	5	3.88	.591
LC2	100	1	5	3.90	.560
LC3	100	1	5	3.94	.422
LC4	100	1	5	3.92	.526
LC5	100	1	5	3.92	.464
Valid N (listwise)	100				

In summary, the provided descriptive statistics offer valuable insights into the perceived effectiveness or importance of various statements within each domain. While some statements enjoy strong consensus and minimal variability (e.g., OM6 and LC3), others exhibit lower mean values and higher variability (e.g., OM1 and PCT1), indicating a more diverse range of opinions. Understanding these patterns can inform decision-making processes, highlighting areas of strength and areas for potential improvement within each domain.
Overall, the descriptive statistics offer a comprehensive overview of respondents' perceptions of operational management in clinical trials. By analyzing these statistics, researchers can identify key areas of strength or concern and tailor interventions or strategies accordingly. Additionally, researchers can use this information to compare responses across different demographic or organizational groups, allowing for a more nuanced understanding of the factors influencing perceptions of operational management in clinical trials. Moving forward, researchers may consider conducting further analyses, such as inferential statistics or qualitative interviews, to explore the underlying reasons behind respondents' perceptions and attitudes, (DiMasi, 2010). Additionally, longitudinal studies could be conducted to assess changes in perceptions over time and evaluate the effectiveness of interventions aimed at improving operational management practices in clinical trials. By employing a multi-faceted approach, researchers can gain deeper insights into the complex dynamics of operational management in clinical trials and identify opportunities for improvement.

5.0 Discussion

In essence, the developing of patient-centric clinical trials, aligned with the overcoming of legal barriers, makes it indispensable to critically analyze the operational management tools and methodologies. The discussion, against this background, synthesizes the insights gained from an analysis of descriptive statistics, highlighting implications for practitioners working in the particular field. During the analysis, significant insights were acquired regarding the perceived effectiveness and importance of different statements in the different domains. There are areas that acquire some kind of consensus among the stakeholders that require more attention.

Patient-centric trials, focusing on the involvement of patients at every stage of the trial process, have been born recently in the field of Clinical Research Methodology (Collier, 2009). This approach constitutes a paradigm shift from traditional models where patients have often been viewed as mere research subjects. These trials have considered patients as active partners and, thereby, a vehicle close to patient needs and preferences. This ensures relevance and an impact that these research outcomes might benefit from. The paradigm facilitates a more collaborative environment where patients provide input on study design, intervention, outcome measures, and recruitment strategies. Such collaboration is important because, other than working on developing the overall quality and deliverability of the study outcomes to reality in clinic settings, it has the potential of improving patient adherence to trial protocols, which are also major determinants of trial outcomes.

Thirdly, operational management models, such as Six Sigma and Lean methodologies, are promising strategies for optimizing trial processes, minimizing variability, and maximizing overall quality and efficiency. Such models describe the way of systematically identifying waste and then eliminating it thereby streamlining processes. Applying these methodologies to clinical trials will reduce delays, improve resource allocation, and enhance communication with stakeholders. For example, applying principles of Six Sigma will lead to more precise data collection processes, which finally yield higher-quality data to reflect patient outcomes. With integration with patient engagement as the main focus, the operational management strategies that the researchers will utilize in order to break through legal barriers and strive to streamline the clinical trials as well as operations for the speedy development of new treatments and medical interventions (Klewes, 2017).

Although this descriptive statistic has given a satisfactory view of the perceptions of the respondents, deeper analysis is required to find the underlying reasons behind these perceptions and attitudes. Data would be used to come up with a basis for higher qualitative methods, which include interviews or focus groups in understanding the motivations and concerns of various actors in clinical trials. Qualitative data will enrich our understanding of the challenges and opportunities presented by patient-centric approaches and operational management strategies.

Longitudinal research would also be able to measure opinion change over time. Observing the impact of an intervention aimed at improving patient engagement or operational efficiency might be a good way for practitioners to develop actionable knowledge that can be applied in practice. Consider, for instance, how researchers can perfect their methodologies by studying how newly established processes influence trial outcome and patient satisfaction.

The findings of this analysis would, therefore, be of immense value to the professionals who work in clinical research. A patient-centric approach might foster trust and transparency, something very crucial to the effective conduct of a trial. Attentive patients who feel their voice is being heard and their concerns taken care of are probably going to be more active in participating and adhering to protocols during participation in a trial thereby improving the quality of collected data. This engagement may also enhance recruitment and retention rates, a common challenge encountered by the clinical trial, resulting in delay and increased costs.

It may, in turn, enhance the overall effectiveness of clinical trials by embracing strategies of operational management. A practitioner employs techniques of process mapping and performance metrics to identify bottleneck points and inefficiencies in trial workflows. The improvement of these factors enables organizations to design an agile as well as responsive trial environment, thus lowering the time taken to put new therapies in the market.

The results of this study can have implications for the results outside of the specific trial itself. Indeed, patient-centric methodologies and operational management strategies through clinical research can contribute to the larger overall vision of improving the research ecosystem. In this way, by establishing a benchmark for best practices in patient involvement and operational excellence, researchers create an innovative climate of collaboration with benefits across stakeholders.

6.0 Conclusion

In summary, operational management models, particularly the Six Sigma approach, offer valuable frameworks for enhancing the efficiency and effectiveness of clinical trials. By applying Six Sigma principles to protocol development, patient enrollment, data management, and resource allocation, improvements in quality outcomes and patient safety can be achieved. However, while Six Sigma offers significant benefits, its adoption and implementation in clinical trial settings may require further exploration and refinement.

Moreover, clinical trials research methodologies, especially RCTs, continue to serve as the gold standard for evaluating treatment efficacy. Despite their strengths, RCTs come with inherent limitations, such as potential biases and ethical considerations. Complementary research methods, such as observational studies, are essential for providing comprehensive insights into treatment effects in real-world settings.

To address legal challenges associated with patient-centric trials, effective navigation of regulatory requirements and compliance with ethical standards is crucial. Collaboration between researchers, regulatory bodies, and legal experts is necessary to develop strategies for overcoming legal barriers and facilitating the conduct of patient-centric trials.

In reviewing the objectives outlined in the study, it is evident that significant progress has been made in understanding various aspects of clinical trial management and research methodologies. The study successfully identified operational management tools, explored legal challenges, and analyzed stakeholders' perceptions regarding the adoption of operational management tools in clinical trials. Additionally, recommendations were provided for addressing legal barriers and conducting patient-centric trials.

However, there are areas for further exploration and refinement. Future research should focus on developing and implementing innovative organizational management strategies such as risk-based monitoring and adaptive trial designs, to optimize trial efficiency and patient safety. Collaboration between stakeholders is crucial for developing effective strategies to address legal challenges and ensure compliance with evolving regulatory standards. Furthermore, efforts should be made to improve patient engagement and participation in clinical trials through the adoption of patient-centric trial designs and tailored communication strategies.

Overall, the study provides valuable insights into the complexities of clinical trial management and research methodologies. By addressing key challenges and embracing innovative solutions, stakeholders can collaborate to advance the field of clinical research and improve patient outcomes on a global scale. In its entirety, the observational paper sheds light on the multifaceted nature of clinical trial administration and research methodologies, highlighting the significance of organizational administration techniques, patient-centric approaches, and legitimate compliance in guaranteeing the success of clinical trials. By tending to key challenges and grasping imaginative arrangements, partners can work together to develop the field of clinical inquiry and move forward persistent results on a worldwide scale.

The findings of the current study have several theoretical implications for the field of clinical trial management and research methodologies. Firstly, the

study contributes to the existing body of knowledge by providing empirical evidence on the effectiveness of various organizational management strategies, such as risk-based monitoring, adaptive trial designs, and quality by design approaches (Clinical Trials Facilitation Group, 2010). These findings extend current theoretical frameworks by demonstrating the practical implications of these strategies in enhancing trial efficiency, integrity, and patient safety.

Moreover, the study adds to the theoretical understanding of patient-centric trial designs and methodologies by highlighting the importance of patient engagement, feedback, and participation in clinical research. By emphasizing the role of patients as active partners in the research process, the study underscores the need for a paradigm shift towards more patient-centered approaches in clinical trial management.

Furthermore, the study contributes to the theoretical discourse on legal challenges associated with clinical trials by identifying key regulatory compliance issues, ethical considerations, and data security concerns. These findings offer valuable insights into the complex interplay between legal, ethical, and practical considerations in the conduct of clinical research, thereby enriching current theoretical frameworks in the field.

Managerial Implications:

From a managerial perspective, the findings of the current study have several practical implications for stakeholders involved in clinical trial management and research. Firstly, the study provides actionable insights for organizational managers and research professionals on the effective implementation of management strategies to optimize trial efficiency and patient safety. By adopting risk-based monitoring, centralized monitoring, and proactive risk identification approaches, managers can enhance the quality and integrity of clinical trial operations.

Moreover, the study offers practical recommendations for researchers, regulators, and industry professionals on addressing legal challenges and ensuring compliance with regulatory requirements. By developing comprehensive strategies for navigating regulatory complexities, ensuring ethical conduct, and safeguarding data security, stakeholders can mitigate legal risks and facilitate the smooth conduct of clinical trials.

In conclusion, the theoretical and managerial implications of the current study underscore the importance of adopting innovative approaches to clinical trial management and research methodologies. By integrating theoretical insights with practical recommendations, stakeholders can enhance the efficiency, integrity, and patient-centricity of clinical trials, ultimately leading to improved patient outcomes and advances in medical research.

Despite the valuable insights obtained from the present study, it is essential to acknowledge several limitations. Firstly, the study relied on self-reported data gathered through surveys, which may be influenced by response bias and social desirability bias. Despite efforts to ensure anonymity and confidentiality, there is a risk of respondents exaggerating or under reporting their responses, potentially impacting the credibility and consistency of the results. Additionally, the study focused on a specific group of participants, namely doctors and managers in bio-pharmaceutical companies. While this group provided valuable insights into clinical trial management, the findings may not be applicable to other populations or settings. Future research should aim to replicate the study with a more diverse sample to improve the generalizability of the findings. Moreover, the study utilized a cross-sectional research design, limiting the ability to establish causal relationships between variables (Buchholzer, 2011). Longitudinal or experimental designs could offer more robust evidence of the effectiveness of management strategies and their impact on clinical trial outcomes. Furthermore, the study predominantly employed quantitative data analysis techniques, potentially overlooking nuanced qualitative insights that could provide a deeper understanding of the research phenomena.

Future Directions for Research: Expanding upon the limitations identified in the current study, several avenues for future research can be explored. Firstly, future studies could incorporate mixed-methods research designs to complement quantitative data with qualitative perspectives. By integrating both quantitative and qualitative approaches, researchers can gain a more comprehensive understanding of the multifaceted factors influencing clinical trial management and research methodologies. Secondly, future research could investigate the effectiveness of specific management strategies across different contexts and settings. For example, comparative studies could evaluate the relative efficacy of various monitoring approaches and trial designs across diverse therapeutic areas, study phases, and geographical regions (Bonham, 2011). This could help identify optimal practices and tailor management strategies to specific research contexts. Overall, future research should endeavor to address the limitations of the current study and advance our comprehension of clinical trial management and research methodologies. By embracing interdisciplinary approaches, innovative methodologies, and collaborative partnerships, researchers can drive meaningful enhancements in the execution and outcomes of clinical trials, ultimately benefiting patients, researchers, and healthcare stakeholders alike.

Declaration Statement

I, declare that this research paper is my original work and has not been submitted for any other degree or publication. I affirm that all sources used in this paper are properly cited and acknowledged. Additionally, I confirm that there are no conflicts of interest related to this research, and any funding received for this project has been disclosed.

Ethics approval and consent to participate= Not applicable

Consent for publication = Yes

Availability of supporting data = Yes provided on

request
Competing interests = No
Funding= No

References

1. Bonham, A., Califf, R., Gallin, E., & Lauer, M. (2011). Developing a Robust Clinical Trials Workforce. IOM Forum on Drug Discovery, Development, and Translation. Washington, D.C.: Institute of Medicine of the National Academies.
2. Brooks, C. (2012). An Independent Perspective on Clinical Trial Timelines: Trending Against Expectations. New York: Citeline.
3. Buchholzer, F. J. (2011). Implementing the Voluntary Harmonization Procedure for Accelerated Clinical Trial Approval. International bio-pharmaceutical Industry, 3(2), 68-69.
4. Califf, R. M., & Muhlbaier, L. H. (2003). Health Insurance Portability and Accountability Act (HIPAA): Must There Be a Trade-Off Between Privacy and Quality of Health Care, or Can We Advance Both? Circulation, 108, 915-918.
5. Califf, R. M., Filerman, G., Murray, R. K., & Rosenblatt, M. (2011). The Clinical Trials Enterprise in the United States: A Call for Disruptive Innovation. IOM Forum on Drug Discovery, Development, and Translation. Washington, D.C.: Institute of Medicine of the National Academies.
6. Cham: Springer. Rubbio, I., Bruccoleri, M., Pietrosi, A., & Ragonese, B. (2019). Digital health technology enhances resilient behaviour: Evidence from the ward. International Journal of Operations & Production Management, 39(4), 594–627.
7. Clinical Trials Facilitation Groups (CTFG). (2010, March). Heads of Medicines Agencies (HMA). Retrieved May 15, 2012, from Guidance document for a Voluntary Harmonisation Procedure (VHP) for the assessment of multinational Clinical Trial Applications: Version 2: http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG/2010_03_VHP_Guidance_v2.pdf
8. Clinical Trials Transformation Initiative (CTTI). (2011). Clinical Trials Transformation Initiative (CTTI) - Identifying Practices that through Broad Adoption will Increase the Quality and Efficiency of Clinical Trials. Retrieved May 25, 2012, from https://www.ctti-clinicaltrials.org/
9. Collier, R. (2009, February 3). Rapidly rising clinical trial costs worry researchers. Canadian Medical Association Journal, 180(3), 277-278.
10. Cutting Edge Information. (2011, December 5). Outsourcing of Phase II Drug Development Now Accounts for 63% of R&D Budgets. Retrieved April 2012, 6, from Cutting Edge Information: http://www.cuttingedgeinfo.com/2011/outsourcing-phase-ii-drug-development/
11. Damodaran, A. (2007). Strategic Risk Taking: A Framework for Risk Management. Upper Saddle River, NJ: Pearson Prentice Hall.
12. Davis, J. R., Nolan, V. P., Woodcock, J., & Estabrook, R. W. (1999). Assuring Data Quality and Validity in Clinical Trials for Regulatory Decision Making: Workshop Report. Roundtable on Research and Development of Drugs, Biologics, and Medical Devices, Institute of Medicine.
13. Deloitte. (2009). Secondary Uses of Electronic Health Record (EHR) Data in Life Sciences. Deloitte Development LLC.
14. Dilts, D. M., & Sandler, A. B. (2006). Invisible Barriers to Clinical Trials: The Impact of Structural, Infrastructural, and Procedural Barriers to Opening Oncology Clinical Trials. Journal of Clinical Oncology, 24(28), 4545-4552.
15. DiMasi, J. A., Feldman, L., Seckler, A., & Wilson, A. (2010, March). Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs. Clinical Pharmacology and Therapeutics, 87(3).
16. DiMasi, J. A., Grabowski, H. G., & Vernon, J. (2004). R&D Costs and Returns by Therapeutic Category. Drug Information Journal, 38, 211-223.
17. DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2005). Reply: Extraordinary claims require extraordinary evidence. Journal of Health Economics, 1034–1044.
18. DiMasi, J., Hansen, R., & Grabowski, H. (2003). The price of innovation: new estimates of drug development costs. Journal of Health Economics, 22(2), 151-185.
19. Downing, N. S., Aminawung, J. A., Shah, N. D., Braunstein, J. B., Krumholz, H. M., & Ross, J. S. (2012, May 16). Regulatory Review of Novel Therapeutics — Comparison of Three Regulatory Agencies. The New England Journal of Medicine.
20. Eisenberg, P., Kaufmann, P., Sigal, E., & Woodcock, J. (2011). Developing a Clinical Trials Infrastructure. IOM Forum on Drug Discovery, Development, and Translation. Washington, D.C.: Institute of Medicine of the National Academies.
21. Eisenstein, E. L., Collins, R., Cracknell, B. S., Podesta, O., Reid, E. D., Sandercock, P., . . . Diaz, R. (2008). Sensible approaches for reducing clinical trial costs. Clinical Trials, 75-84.
22. Eisenstein, E. L., Lemons II, P. W., Tardiff, B. E., Schulman, K. A., Jolly, M. K., & Califf, R. M. (2004). Reducing the costs of phase III cardiovascular clinical trials. American Heart Journal, 149(3), 482-488.
23. Embi, P. J., Jain, A., Clark, J., Bizjack, S., Hornung, R., & Harris, C. M. (2005). Effect of a Clinical Trial Alert System on Physician Participation in Trial Recruitment. Archives of Internal Medicine, 2272-2277.
24. English, R., Lebovitz, Y., & Giffin, R. (2010). Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary. Institute of Medicine of the National Academies, Forum on Drug Discovery, Development, and Translation Board on Health Sciences Policy. Washington, D.C.: The National Academies Press.

25. Getz, K. A. (2006, December 1). Hitching a Ride with the Speed Demons of Drug Development. Retrieved December 15, 2011, from Applied Clinical Trials Online: http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.j...
26. Getz, K. A. (2007, September 1). Global Clinical Trials Activity in the Details. Retrieved March 21, 2012, from Applied Clinical Trials Online: http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article... 3
27. Getz, K. A. (2008, May 1). The Heavy Burden of Protocol Design. Retrieved July 23, 2012, from Applied Clinical Trials
28. Huang, H., Leone, D., Caporuscio, A., & Kraus, S. (2020). Managing intellectual capital in healthcare organizations. A conceptual proposal to promote innovation. Journal of Intellectual Capital. https://doi.org/10.1108/JIC-02-2020-0063. in print.
29. Huber, C., & G¨ artner, C. (2018). Digital transformations in healthcare professionals' work: Dynamics of autonomy, control and accountability. Management Revue, 29(2), 139–161.
30. Imison, C., Castle-Clarke, S., Watson, R., & Edwards, N. (2016). Delivering the benefits of digital health care.
31. Kivimaa, P., Boon, W., Hyysalo, S., & Klerkx, L. (2019). Towards a typology of intermediaries in sustainability transitions: A systematic review and a research agenda. Research Policy, 48(4), 1062–1075.
32. Klewes, J., Popp, D., & Rost-Hein, M. (2017). Digital transformation and communications: How key trends will transform the way companies communicate. In J. Klewes, D. Popp, & M. Rost-Hein (Eds.), Out-thinking Organizational Communications. Management for Professionals. Cham: Springer.
33. Kohl, S., Schoenfelder, J., Fügener, A., & Brunner, J. O. (2019). The use of Data Envelopment Analysis (DEA) in healthcare with a focus on hospitals. Health Care Management Science, 22, 245–286.
34. Kostkova, P. (2015). Grand challenges in digital health. Frontiers in Public Health, 3, 134.
35. Kraus, S., Breier, M., & Dasí-Rodríguez, S. (2020). The art of crafting a systematic literature review in entrepreneurship research. International Entrepreneurship and Management Journal, 16, 1023–1042. https://doi.org/10.1007/s11365-020-00635- 4.
36. Laurenza, E., Quintano, M., Schiavone, F., & Vrontis, D. (2018). The effect of digital technologies adoption in healthcare industry: A case based analysis. Business Process Management Journal, 24(5), 1124–1144.
37. Leonard, K. J. (2004). The role of patients in designing health information systems: The case of applying simulation techniques to design an Electronic Patient Record (EPR) interface. Health Care Management Science, 7(4), 275–284.
38. Manogaran, G., Lopez, D., Thota, C., Abbas, K. M., Pyne, S., & Sundarasekar, R. (2017). Big data analytics in healthcare internet of things. In H. Qudrat-Ullah, & P. Tsasis (Eds.), Innovative healthcare systems for the 21st century. Understanding Complex Systems.
39. Mas-Tur, A., Kraus, S., Brandtner, M., Ewert, R., & Kürsten, W. (2020). Advances in management research: a bibliometric overview of the Review of Managerial Science. Review of Managerial Science, 14(5), 933–958.
40. Mazor, I., Heart, T., & Even, A. (2016). Simulating the impact of an online digital dashboard in emergency departments on patients length of stay. Journal of Decision Systems, 25(sup1), 343–353.
41. Melchiorre, M. G., Papa, R., Rijken, M., Van Ginneken, E., Hujala, A., & Barbabella, F. (2018). EHealth in integrated care programs for people with multimorbidity in Europe: Insights from the ICARE4EU project. Health Policy, 122(1), 53–63.
42. Monti, A., Coleman, C. (2016). Future of Health: Seven visions of the future of healthcare. In: The Telegraph. Retrieved online: http://tgr.ph/futureofhealth. Accessed: 09/07/2019.
43. Nudurupati, S. S., Bhattacharya, A., Lascelles, D., & Caton, N. (2015). Strategic sourcing with multi-stakeholders through value co-creation: An evidence from global health care company. International Journal of Production Economics, 166, 248–257.
44. Nuffield Trust. Jefferies, J. G., Bishop, S., & Hibbert, S. (2019). Customer boundary work to navigate institutional arrangements around service interactions: Exploring the case of telehealth. Journal of Business Research. April 2019.
45. Ozdemir, Z., Barron, J., & Bandyopadhyay, S. (2011). An Analysis of the adoption of digital health records under switching costs. Information Systems Research, 22(3), 491–503.
46. Patrício, L., Teixeira, J. G., & Vink, J. (2019). A service design approach to healthcare innovation: From decision-making to sense-making and institutional change. AMS Review, 9, 115–120.
47. Parviainen, P., Tihinen, M., K¨ aari ¨ ainen, ¨ J., & Teppola, S. (2017). Tackling the digitalization challenge: How to benefit from digitalization in practice. International Journal of Information Systems and Project Management, 5(1), 63–77.
48. Reddy, P., & Brahm, S. (2016). Digitalisation: The future of healthcare. Journal of Business Management, (11), 126–135.
49. Reis, J., Amorim, M., Mel˜ ao, N., & Matos, P. (2018). In Digital transformation: a literature review and guidelines for future research (pp. 411–421).
50. Springer, Cham. Marques, I. C., & Ferreira, J. J. (2020). Digital transformation in the area of health: Systematic review of 45 years of evolution. Health and Technology, 10, 575–586.